Glenmark Pharmaceuticals Inc., USA is recalling 8,520 bottles of Theophylline (Anhydrous) Extended-Release Tablets, 600 mg. This recall was initiated after testing revealed that the tablets failed a dissolution test, meaning the medication may not release into the body as intended. Consumers should contact their healthcare provider or pharmacist to discuss their treatment and determine if they have the affected medication.
If an extended-release medication fails to dissolve properly, it may release the drug too slowly, making it ineffective, or too quickly, which could lead to toxic levels of the medication in the bloodstream. This is particularly concerning for theophylline, which requires precise dosing to treat respiratory conditions safely.
You have 2 options:
Rx Only; Manufactured by Glenmark Pharmaceuticals Limited in India.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.